Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

Summary

The purpose of this study is to assess the safety and tolerability of escalating doses of SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase 2 dose.

Timeline

Start

2007-02

Primary completion

2008-12

Completion

2009-03

Publications

• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009 Mar;9(3):153-66. doi: 10.1038/nrc2602.

Drugs

Indications